The usual use of Sotan (sunitinib) for advanced kidney cancer is a 4/2 regimen of 12.5 mg*4 tablets once a day for four weeks with a two-week break for a total of six weeks. Adverse reactions such as yellowing of the skin, painful erythema of the skin on the hands and feet, diarrhea, mouth ulcers, and a decrease in white blood cells and platelets may occur during the administration of Sotan, with a higher probability of a decrease in platelets. The following items need to be monitored after discharge from the hospital: Cycle 1: routine blood tests every week for the first four weeks and liver and kidney functions every 2 weeks; Cycle 2 and follow-up: routine blood tests every 2 weeks, especially in the 3rd and 4th weeks of medication. At least once every 3-6 months, thyroid function and heart ultrasound should be reviewed. Adverse reactions: myelosuppression that occurs during targeted therapy for kidney cancer, mainly manifested as 1. neutropenia. After the occurrence of grade 3/4 or higher adverse reactions to oral sunitinib, the current regimen or dose adjustment strategies are mainly as follows: regimens are 4/2 to 2/1 regimen, 37.5 mg continuous dosing regimen, and other dose reduction regimens. Currently, there is a high international acceptance of the 4/2 regimen to 2/1 regimen. The regimen or dose adjustment of targeted drugs should adhere to the principle of individualization. 2, platelet drop during medication, such as below 50,000, should immediately discontinue treatment with Sotan and promptly come to the hospital for outpatient treatment. 3, liver function abnormalities Dose priority principle: In terms of the principles of adverse reactions, experts agree that: most adverse reactions are mild to moderate in intensity (grade 1/2), occurring early in treatment, can be well controlled through routine clinical management and do not require treatment discontinuation or permanent dose reduction; some of the more severe grade 3/4 adverse reactions require active clinical intervention (in some cases dose adjustment or reduction), and after symptom control, adequate drug exposure and prolonged dosing should be maintained. For adverse reactions where control fails, resulting in intolerable or life-threatening effects for the patient (hepatotoxicity), discontinuation of the drug or a change in treatment regimen may be considered; patients and physicians should be aware of the clinical management aspects of adverse reactions to treatment discontinuation or dose reduction, and experts agree that: active management of adverse reactions, prolonged The experts agreed that active management of adverse reactions, prolonging the duration of drug administration, and ensuring adequate drug dose exposure are critical to maximize the clinical efficacy of targeted drugs.